Literature DB >> 656704

The acute effects of nicotine, tobacco smoke and carbon monoxide on myocardial oxygen tension in the anaesthetized cat.

R D Rink.   

Abstract

1 The acute effects of nicotine, tobacco smoke, and carbon monoxide on myocardial oxygen tension (MPo(2)) were estimated amperometrically in 33 anaesthetized open-chest cats with a glass-insulated 25 mum platinum cathode within a 22-gauge needle implanted in the left ventricular wall.2 MPo(2) was 1.6-60 mmHg (mean 23.5 mmHg) when arterial Po(2) was >80 mmHg. Sequential intravenous infusions of nicotine (2-3 mug/kg every 45 s) or intracheal puffs (3-5 ml) of tobacco smoke commonly produced transitory increases (25-35 mmHg) of arterial pressure and 4-6 mmHg increments of MPo(2). Intratracheal puffs (5 ml) of 5% carbon monoxide sufficient to increase carboxyhaemoglobin from 0.8 to 1.5% to 4-7% had no effect on arterial Po(2) or blood pressure but typically decreased MPo(2) by approximately 1-4 mmHg. Augmentation of MPo(2) often succeeded carbon monoxide administration.3 Arterial hypoxia (arterial Po(2) < 60 mmHg) reduced mean MPo(2) to 14.4 mmHg but anoxic levels were not observed. Pressor responses to nicotine and tobacco smoke were accompanied by small increases (usually 1-3 mmHg) of MPo(2). Puffs of 5% carbon monoxide had less effect than during normoxia. Locations of low MPo(2) (<10 mmHg) were unaffected as carboxyhaemoglobin was raised to 7-11% during hypoxaemia.4 It is concluded that nicotine and tobacco smoke cause augmentation of myocardial oxygen supply, even during moderate hypoxaemia. By contrast, smoking dosages of carbon monoxide have the potential of producing a small reduction of MPo(2) during normoxia, but the effect is negligible during moderate hypoxaemia.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 656704      PMCID: PMC1668045          DOI: 10.1111/j.1476-5381.1978.tb07766.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  Coronary blood flow and cardiac oxygen metabolism during nicotine-induced increases in left ventricular work.

Authors:  I E FORTE; A J WILLIAMS; L POTGIETER; J E SCHMITTHENNER; J H HAFKENSCHIEL; C RIEGEL
Journal:  Ann N Y Acad Sci       Date:  1960-09-27       Impact factor: 5.691

2.  The effect of levarterenol on polarographic myocardial oxygen, the epicardial electrocardiogram and contraction in nonischemic dog hearts and experimental acute regional ischemia.

Authors:  J J SAYEN; A H KATCHER; W F SHELDON; C M GILBERT
Journal:  Circ Res       Date:  1960-01       Impact factor: 17.367

3.  Intramural pressure in the left ventricle of the dog.

Authors:  G Brandi; M McGregor
Journal:  Cardiovasc Res       Date:  1969-10       Impact factor: 10.787

4.  Release of adenosine by the normal myocardium in dogs and its relationship to the regulation of coronary resistance.

Authors:  R Rubio; R M Berne
Journal:  Circ Res       Date:  1969-10       Impact factor: 17.367

5.  Intramyocardial oxygen tension.

Authors:  A J Moss
Journal:  Cardiovasc Res       Date:  1968-07       Impact factor: 10.787

6.  The effect of nicotine on effective and total coronary blood flow in the anesthetized closed-chest dog.

Authors:  G Leb; F Derntl; E Robin; R J Bing
Journal:  J Pharmacol Exp Ther       Date:  1970-05       Impact factor: 4.030

7.  Blood gas tensions and acid-base balance in awake cats.

Authors:  D A Herbert; R A Mitchell
Journal:  J Appl Physiol       Date:  1971-03       Impact factor: 3.531

8.  The effect of low-nicotine cigarettes on angina pectoris.

Authors:  W S Aronow; A J Swanson
Journal:  Ann Intern Med       Date:  1969-09       Impact factor: 25.391

9.  Electrode size and tissue pO2 measurement in rats exposed to air or high pressure oxygen.

Authors:  D Jamieson; H A van den Brenk
Journal:  J Appl Physiol       Date:  1965-05       Impact factor: 3.531

10.  Carbon monoxide-induced arterial hypoxemia.

Authors:  J S Brody; R F Coburn
Journal:  Science       Date:  1969-06-13       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.